论文部分内容阅读
目的探讨D-Ⅱ聚体(D-dimer)含量评价肾病综合征患者凝血、纤溶活性的临床意义。方法采用定量酶联免疫吸附法测定不同病理类型的肾病综合征87例,以及正常对照组30例患者内D-Ⅱ聚体含量,比较各组D-Ⅱ聚体含量。结果D-Ⅱ聚体阳性发生率和含量:各组肾病综合征患者均明显高于对照组,P<0.01;在各组肾病综合征患者中,膜性肾病组高于其他组,P<0.05。结论D-Ⅱ聚体增高显示肾病综合征患者体内有微血栓形成和溶解同时进行的活化血栓形成,需积极抗凝治疗。
Objective To investigate the clinical significance of D-dimer in the evaluation of coagulation and fibrinolytic activity in patients with nephrotic syndrome. Methods Quantitative enzyme-linked immunosorbent assay was used to determine the content of D-dimer in 87 patients with different pathological types of nephrotic syndrome and 30 normal controls. The content of D-dimer in each group was compared. Results The positive incidence and content of D-dimer in all patients with nephrotic syndrome were significantly higher than those in control group (P <0.01). Among all nephrotic syndrome patients, membranous nephropathy was higher than other groups (P <0.05) . Conclusions D-dimer increase shows that patients with nephrotic syndrome have microthrombus formation and lysis-activated thrombosis simultaneously, which require active anticoagulation therapy.